BioXcel Therapeutics Inc (BTAI)vsZoetis Inc (ZTS)
BTAI
BioXcel Therapeutics Inc
$0.07
-37.11%
HEALTHCARE · Cap: $5.10M
ZTS
Zoetis Inc
$82.96
+0.47%
HEALTHCARE · Cap: $33.45B
Smart Verdict
WallStSmart Research — data-driven comparison
Zoetis Inc generates 1279415% more annual revenue ($9.49B vs $742,000). ZTS leads profitability with a 26.4% profit margin vs 0.0%. ZTS earns a higher WallStSmart Score of 56/100 (C).
BTAI
Avoid27
out of 100
Grade: F
ZTS
Buy56
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+27.7%
Fair Value
$2.24
Current Price
$0.07
$2.17 discount
Margin of Safety
+11.2%
Fair Value
$144.94
Current Price
$82.96
$61.98 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 51.7% year-over-year
Conservative balance sheet, low leverage
Every $100 of equity generates 75 in profit
Strong operational efficiency at 38.2%
Safe zone — low bankruptcy risk
Keeps 26 of every $100 in revenue as profit
Attractively priced relative to earnings
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Trading at 10.2x book value
Expensive relative to growth rate
Revenue declined 1.3%
Earnings declined 11.8%
Comparative Analysis Report
WallStSmart ResearchBull Case : BTAI
The strongest argument for BTAI centers on Revenue Growth, Debt/Equity. Revenue growth of 51.7% demonstrates continued momentum.
Bull Case : ZTS
The strongest argument for ZTS centers on Return on Equity, Operating Margin, Altman Z-Score. Profitability is solid with margins at 26.4% and operating margin at 38.2%.
Bear Case : BTAI
The primary concerns for BTAI are EPS Growth, Market Cap, Profit Margin.
Bear Case : ZTS
The primary concerns for ZTS are Price/Book, PEG Ratio, Revenue Growth. Debt-to-equity of 2.80 is elevated, increasing financial risk.
Key Dynamics to Monitor
BTAI profiles as a hypergrowth stock while ZTS is a declining play — different risk/reward profiles.
ZTS carries more volatility with a beta of 0.68 — expect wider price swings.
BTAI is growing revenue faster at 51.7% — sustainability is the question.
ZTS generates stronger free cash flow (717M), providing more financial flexibility.
Bottom Line
ZTS scores higher overall (56/100 vs 27/100), backed by strong 26.4% margins. BTAI offers better value entry with a 27.7% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
BioXcel Therapeutics Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
BioXcel Therapeutics, Inc., a clinical-phase biopharmaceutical company, focuses on the development of artificial intelligence-based drugs in the fields of neuroscience and immuno-oncology in the United States. The company is headquartered in New Haven, Connecticut.
Zoetis Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Zoetis Inc. is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?